Autoimmune Disease Diagnostics Market Analysis

Autoimmune Disease Diagnostics Market Analysis

To get key market trends

  Download Free Sample

The market, by product, is bifurcated into reagents and consumables, and instruments. The reagents and consumables segment dominated the market with a revenue of around USD 3.5 billion in 2023.
 

• The rising incidence of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis is driving the demand for diagnostic tests. As more patients require testing, the need for reagents and consumables also increases.
   
• Continuous advancements in diagnostic technologies, such as enzyme-linked immunosorbent assays (ELISA), polymerase chain reaction (PCR), and immunofluorescence assays, have led to a higher demand for specialized reagents and consumables. These innovations enhance the accuracy and efficiency of autoimmune disease diagnostics.
   
• Moreover, increased awareness about autoimmune diseases and the importance of early diagnosis among healthcare providers and patients has resulted in higher testing rates. Early detection often involves multiple tests, further boosting the demand for reagents and consumables.
   

The autoimmune disease diagnostics market by disease type, is bifurcated into systemic autoimmune disease and localized autoimmune disease. The localized autoimmune disease segment dominated the market with a revenue of around USD 3.7 billion in 2023 and is expected to grow at a CAGR of 5.7%.
 

• The high prevalence of localized autoimmune diseases, such as Type 1 diabetes, multiple sclerosis, and inflammatory bowel diseases (Crohn's disease and ulcerative colitis), drives the demand for diagnostic tests. These diseases often require ongoing monitoring and frequent testing.
   
• Continuous advancements in diagnostic technologies, such as molecular diagnostics, imaging techniques, and cancer biomarker discovery, are enhancing the accuracy and efficiency of diagnosing localized autoimmune diseases. Innovations like next-generation sequencing (NGS) and advanced immunoassays are crucial for early and precise diagnosis.
   
• Moreover, growing awareness about localized autoimmune diseases and the importance of early diagnosis among healthcare providers and patients has led to higher testing rates. Public health initiatives and screening programs promote early detection and intervention, further boosting the demand for diagnostic tests.
   

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibody tests, autoantibody tests, c-reactive protein (CRP), complete blood count (CBC), urinalysis, and other tests. The antinuclear antibody tests segment was valued at over USD 2.3 billion in 2023 and is anticipated to grow at a 6.1% CAGR from 2024-2032.
 

• This dominant market growth is primarily attributed to the high prevalence of chronic ailments and diseases that attack the immune system, such as Type 1 diabetes, myasthenia gravis, Addison's disease, and rheumatoid arthritis.
   
• Antinuclear antibody tests detect antinuclear antibodies in the blood. Myasthenia gravis is a genetically susceptible autoimmune disease. According to NCBI, in 2021, the prevalence rate of myasthenia gravis in the U.S. was around 20 individuals per 100,000 population, and it is increasing at a steady pace. Thus, the high prevalence of genetic autoimmune diseases is expected to expedite the autoimmune disease diagnostics industry's growth in the coming years.
   

By end-use, the autoimmune disease diagnostics market is segmented into hospitals, diagnostic centers, and other end-users. The hospitals segment accounted for a majority market share of 53.5% in 2023 and is expected to proliferate the market growth during the analysis period. This significant market share is owing to the surged adoption of autoimmune disease diagnostic procedures in hospitals associated to complex interventional surgeries.
 

• Hospitals consist of sophisticated technology labs, offer effective physiotherapy sessions, provide improved patient care and counselling, and offer other services that ensure market expansion and create demand for these facilities.
   
• Furthermore, the rise in the incidence of several chronic and neurological diseases that can result in autoimmune conditions will drive market expansion. The increasing availability of highly skilled medical and healthcare professionals, along with advanced facilities, are key factors contributing to segmental progression, thereby leading to overall market growth.
   

North America autoimmune disease diagnostics market accounted for USD 1.9 billion in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The U.S. market is projected to exceed USD 2.9 billion by 2030. This dominant market share is attributed to several factors, including the rising autoimmune disease burden, increasing healthcare expenditure, product launches, and the presence of major players across the country.
   
• According to the National Stem Cell Foundation, approximately 5% to 8% of the total U.S. population suffers from multiple autoimmune disorders, accounting for around 1 in 15 people undergoing autoimmune disease diagnostics treatment.
   
• Additionally, as per reports from the National Institute of Environmental Health Sciences, in 2021, around 24 million people in the U.S. were affected by autoimmune diseases, with an additional 8 million people having autoantibodies—blood molecules that might increase the chances of developing autoimmune disease. Furthermore, increasing awareness and favourable government initiatives are expected to drive lucrative market growth.
   
• Technologically advanced diagnostic centers and the adoption of automation technology in diagnosis and treatment will provide ample growth opportunities. Moreover, the presence of major players in the country and the launch of novel products are expected to fuel the regional market statistics.